The changes of cytokines level in aqueous humor of patients with neovascular age-related macular degeneration following intravitreal brolucizumab.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220511001

Enrollment

Registered

2022-05-11

Start date

2023-02-09

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related macular degeneration Age-related macular degeneration Brolucizumab

Interventions

Patients with nAMD and received intravitreal brolucizumab injection

Basic Science

Brolucizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with neovascular age-related macular degeneration (nAMD) diagnosed by fundus fluorescein angiography (FFA) and/or optical coherence tomography (OCT). 2. Patients receiving intravitreal brolucizumab injection

Exclusion criteria

Exclusion criteria: 1. Patients with other retinal diseases 2. History of or active ocular inflammation or infection in either eye 3. History of or active systemic autoimmune diseases or cancer

Design outcomes

Primary

Measure	Time frame
Changes in cytokine levels 4 weeks after first injection Milliplex Multiplex immunoassays	—

Secondary

Measure	Time frame
Subretinal fluid 4 and 12 weeks after first injection OCT images,Intraocular inflammation 4 and 12 weeks after first injection Physical examination	—

Countries

Thailand

Contacts

Public ContactVaris Ruamviboonsuk

Faculty of Medicine, Chulalongkorn University

varis.ru@chula.ac.th66875100383

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026